ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 1738 • 2016 ACR/ARHP Annual Meeting

    Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison

    Peter Nash1, Iain B McInnes2, Philip J Mease3, Ernest H. Choy4,5, Howard Thom6, Chrysostomos Kalyvas7, Kunal Gandhi8, Shephard Mpofu9 and Steffen Jugl9, 1Department of Medicine, University of Queensland, Brisbane, QLD, Australia, 2University of Glasgow, Glasgow, United Kingdom, 3Swedish Medical Center and University of Washington, Seattle, WA, 4Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, 5CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, 6University of Bristol, Bristol, United Kingdom, 7MAPI Group, Houten, Netherlands, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. A head-to-head…
  • Abstract Number: 1680 • 2016 ACR/ARHP Annual Meeting

    Apremilast Monotherapy As the First Systemic Treatment in DMARD-Naive Patients with Active Psoriatic Arthritis: 3-Year Treatment Results

    Alvin F. Wells1, Christopher J. Edwards2,3, Alan J. Kivitz4, Paul Bird5, Dianne Nguyen6, Kamal Shah6, Lichen Teng6 and Jacob A Aelion7, 1Rheumatology and Immunotherapy Center, Franklin, WI, 2University of Southampton, Southampton, United Kingdom, 3University Hospital Southampton, Southampton, United Kingdom, 4Altoona Center for Clinical Research, Duncansville, PA, 5Combined Rheumatology Practice, Kogarah, Australia, 6Celgene Corporation, Summit, NJ, 7West Tennessee Research Institute, Jackson, TN

    Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes joint inflammation and other manifestations of psoriatic arthritis…
  • Abstract Number: 1740 • 2016 ACR/ARHP Annual Meeting

    Long-Term Improvements in Physical Function of DMARD-Naive and DMARD/Biologic-Experienced Psoriatic Arthritis Patients Treated with Apremilast: Data from a Large Database of 4 Phase III Clinical Trials

    Philip J Mease1, Alvin F Wells2, Jürgen Wollenhaupt3, Stephen Hall4, Filip van Den Bosch5, Eric Lespessailles6, Melissa McIlraith7, Dianne Nguyen7, Lichen Teng7 and Christopher J Edwards8, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Rheumatology & Immunotherapy Center, Franklin, WI, 3Schön Klinik Hamburg Eilbek, Hamburg, Germany, 4Monash University, CabriniHealth, Melbourne, Australia, 5UZ Gent, Gent, Belgium, 6University of Orléans, Orléans, France, 7Celgene Corporation, Summit, NJ, 8University Hospital Southampton, Southampton, United Kingdom

    Background/Purpose: Improving and preserving patient (pt) physical function is an important goal in managing psoriatic arthritis (PsA). Apremilast (APR) has been shown to improve signs…
  • Abstract Number: 1683 • 2016 ACR/ARHP Annual Meeting

    Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Philip J Mease1, Chitra Karki2, Mei Liu2, Arthur Kavanaugh3, Renganayaki Pandurengan2, Christopher T. Ritchlin4, Jacqueline B. Palmer5 and Jeffrey D. Greenberg2,6, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3University of California San Diego, La Jolla, CA, 4Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6New York University School of Medicine, New York, NY

    Background/Purpose: Although spinal involvement has been well studied in ankylosing spondylitis,1 very few studies in psoriatic arthritis (PsA) have characterized patients with axial involvement. The…
  • Abstract Number: 1743 • 2016 ACR/ARHP Annual Meeting

    Prevalence of Inflammatory Neck Pain in a Cohort of Patients with Psoriatic Arthritis and Its Association with Clinical and Radiographic Features

    Osvaldo Luis Cerda, Margarita Landi, Cecilia Zaffarana, Josefina Gallino Yanzi, Emilce Schneeberger and Gustavo Citera, Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

    Background/Purpose: Cervical inflammatory pain is very common and rarely studied in patients with Psoriatic Arthritis (PsA). The purpose of our study was to evaluate the…
  • Abstract Number: 1687 • 2016 ACR/ARHP Annual Meeting

    Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis

    Alice B. Gottlieb1, Laura C. Coates2, Catherine L. Shuler3, Chen-Yen Lin3, Susan R. Moriarty3, Chin H. Lee3 and Philip J Mease4, 1Tufts University School of Medicine, Boston, MA, 2University of Leeds, Leeds, United Kingdom, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: PsA is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. Ixekizumab (IXE) is an IgG4 mAb that binds…
  • Abstract Number: 2006 • 2016 ACR/ARHP Annual Meeting

    Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study

    Mirjam K. de Vries1, Elizabeth V. Arkema1, Jerker Jonsson2, Judith Bruchfeld3, Lennart TH Jacobsson4 and Johan Askling1,5, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 2Infectious Diseases Unit, Karolinska University Hospital, The Public Health Agency of Sweden, Stockholm, Sweden, 3Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, 4Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 5Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at a well-documented increased risk of tuberculosis (TB) compared to the general population, both with and without treatment…
  • Abstract Number: 1059 • 2015 ACR/ARHP Annual Meeting

    Increased Risk of Atrioventricular Block, Atrial Fibrillation and Pacemaker Implantation in Ankylosing Spondylitis, Undifferentiated Spondylarthritis and Psoriatic Arthritis Compared to the General Population

    Karin Bengtsson1, Helena Forsblad-d'Elia2, Elisabeth Lie1, Eva Klingberg1, Mats Dehlin1, Sofia Exarchou3, Ulf Lindström1, Johan Askling4 and Lennart TH Jacobsson1, 1Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 2Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, 3Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: There is a known association between conduction disturbances and ankylosing spondylitis (AS). The risk of conduction disturbances in other phenotypes of spondylarthritis (SpA) is…
  • Abstract Number: 1629 • 2015 ACR/ARHP Annual Meeting

    Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis

    Matthias H. Thomas1, Klaus Krüger2, Pee Aries3, Martin Bohl-Buehler4, Jan Brandt-Juergens5, Verena Rickert6 and Siegfried Wassenberg7, 1Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany, 2Praxiszentrum St. Bonifatius, München, Germany, 3Rheumatologie im Struenseehaus, Hamburg, Germany, 4Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, 5Praxis Brandt-Juergens/Karberg, Berlin, Germany, 6Medical Affairs, MSD Sharp&Dohme GmbH, Haar, Germany, 7Fachkrankenhaus, Ratingen, Germany

    Background/Purpose: Golimumab (GOL) has shown its efficacy and safety in various randomized clinical trials with accurately selected patients. Data from daily clinical practice in Germany…
  • Abstract Number: 1715 • 2015 ACR/ARHP Annual Meeting

    Sensivity and Specificity of Clinical Criteria to Identify Patients in Ultrasound Remission in Psoriatic Arthritis

    Brigitte Michelsen1, Andreas P Diamantopoulos2, Hilde Berner Hammer3, Arthur Kavanaugh4 and Glenn Haugeberg1,5,6, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Haugesund Rheumatism Hospital, Haugesund, Norway, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4University of California, San Diego School of Medicine, LaJolla, CA, 5Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway, 6Rheumatology, Martina Hansens Hospital, Gjettum, Norway

    Background/Purpose: To date, although several have been proposed, there are no validated remission criteria in psoriatic arthritis (PsA). Validated criteria for minimal disease activity (MDA) in…
  • Abstract Number: 37 • 2015 ACR/ARHP Annual Meeting

    Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors

    Luis Rodriguez-Rodriguez1,2, Pedro P Perrotti3, Adrìa Aterido3, Jesús Tornero4, Carlos Ferrandiz5, Juan D. Cañete6, Antonio Fernandez-Nebro7, Javier P Gisbert8, Eugeni Domènech9,10, María López-Lasanta3, Sara Marsal3, Benjamín Fernández-Gutiérrez1,11 and IMID Consortium, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 3Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 4Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, 5Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 6Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, 7Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, 8Gastroenterology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 9Gastroenterology & Hepatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 10CIBERehd, Madrid, Spain, 11Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose : Our aim was 1) to analyze the association between demographic and traditional cardiovascular risk factors (CVRF) and cardiovascular disease (CVD) in subjects affected…
  • Abstract Number: 1726 • 2015 ACR/ARHP Annual Meeting

    Reliability of Radiographic Assessment of Psoriatic Arthritis Mutilans

    Dennis Wong1, Ker-Ai Lee2, Richard J. Cook3, Dafna Gladman4, Lihi Eder4 and Vinod Chandran4, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 3Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 4Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis mutilans (PsAM) is the most severe form of Psoriatic arthritis (PsA). Research on PsAM has been hampered by the lack of an…
  • Abstract Number: 103 • 2015 ACR/ARHP Annual Meeting

    Axial Disease in Psoriatic Arthritis: Genetic Biomarkers of Psoriatic Spondyloarthritis

    Deepak R. Jadon1, John Bowes2, Anne Barton3, Raj Sengupta1, Alison L Nightingale4, Mark Lindsay5, Eleanor Korendowych1, Graham Robinson6 and Neil J. McHugh7, 1Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, 3Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, 4Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 5Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, 6Royal United Hospital, Bath, United Kingdom, 7Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom

    Background/Purpose: A lack of well-characterised clinical cohorts has impeded research of the genetics of axial disease in psoriatic arthritis (PsA). We sought to determine genetic…
  • Abstract Number: 2495 • 2015 ACR/ARHP Annual Meeting

    Tele-Monitoring of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis

    Alexander Langer1 and Hans-Eckhard Langer2, 1Department of Computer Science, RWTH Aachen University, Aachen, Germany, 2RHIO (Rheumatology, Immunology, and Osteology), Duesseldorf, Germany

    Background/Purpose: There is evidence that tight control of rheumatoid arthritis improves outcome. In daily practice this aim is constricted by logistic limitations such as a…
  • Abstract Number: 165 • 2015 ACR/ARHP Annual Meeting

    Validation of a New Ultrasound Criteria for Subclinical Synovitis in Chronic Inflammatory Polyarthritis

    Julio Ramírez1, Jose Inciarte-Mundo2, Andrea Cuervo1, Virginia Ruiz-Esquide2, M. Victoria Hernández3, Raimon Sanmarti2 and Juan D. Cañete2, 1Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, 2Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, 3Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain

    Background/Purpose: We have previously reported that patients with subclinical synovitis defined by synovial hypertrophy grade >2 (SH>2) plus power Doppler (PD) signal had  higher disease…
  • « Previous Page
  • 1
  • …
  • 83
  • 84
  • 85
  • 86
  • 87
  • …
  • 93
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology